Teleflex Incorporated (LON:0ADI)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 4.19B +7.7% |
| Revenue (ttm) | 1.70B +110.9% |
| Net Income | -777.58M |
| EPS | -17.65 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 15.30 |
| Dividend | 1.02 (1.15%) |
| Ex-Dividend Date | May 22, 2026 |
| Volume | 51 |
| Open | 120.33 |
| Previous Close | 128.04 |
| Day's Range | 120.33 - 120.33 |
| 52-Week Range | 120.33 - 135.90 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Teleflex
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and col... [Read more]
News
Teleflex price target raised to $158 from $145 at UBS
UBS raised the firm’s price target on Teleflex (TFX) to $158 from $145 and keeps a Neutral rating on the shares. The firm updated its model post the Q2 earnings…
Teleflex price target raised to $150 from $143 at Truist
Truist analyst Richard Newitter raised the firm’s price target on Teleflex (TFX) to $150 from $143 and keeps a Hold rating on the shares after its Q2 earnings beat. A…
Teleflex price target raised to $155 from $150 at Raymond James
Raymond James raised the firm’s price target on Teleflex (TFX) to $155 from $150 and keeps an Outperform rating on the shares. Teleflex delivered solid Q2 results, raised EPS guidance,…
Teleflex Earnings Call Transcript: Q2 2026
Q2 2026 saw strong Vascular and Surgical growth, offset by Interventional integration delays, leading to lowered revenue guidance but higher adjusted EPS outlook. Strategic divestitures and capital returns are progressing, with innovation milestones in EZPLAZ and Freesolve supporting future growth.
Teleflex Earnings release: Q2 2026
Teleflex released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Teleflex Slides: Q2 2026
Teleflex has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Teleflex Quarterly report: Q2 2026
Teleflex has published its Q2 2026 quarterly earnings report on August 6, 2026.
Teleflex raises 2026 adjusted EPS view 6.90-$7.20 from $6.25-$6.55
2026 EPS consensus $6.67. Lowers 2026 revenue growth view to 13.4%-14.4% from 14.4%-15.4% from 2025 revenue of $1.98B, consensus $2.29B.
Teleflex reports Q2 adjusted EPS $1.76, consensus $1.28
Reports Q2 cont-op revenue $570.3M, consensus $559.57M. “We delivered a strong Q2, led by excellent performance in our Vascular and Surgical businesses, while continuing to take decisive actions to st...
Teleflex Announces Quarterly Dividend
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. Th...
Teleflex Reports Second Quarter Financial Results and Full Year 2026 Outlook
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 30, 2026. Second quarter 2026 continuing operations f...
Teleflex Medical OEM Launches as INGENYX to Empower Tomorrow's MedTech Innovators
Combining leading in-house expertise with platform-enhancing investments to accelerate advances in engineering, innovation and manufacturing capabilities serving global medical device innovators Marks...
Teleflex Completes Strategic Divestiture of OEM Business for $1.5 Billion
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced it has completed the previously disclosed divestiture of its OEM busin...
Teleflex price target raised to $159 from $147 at Needham
Needham analyst Mike Matson raised the firm’s price target on Teleflex (TFX) to $159 from $147 and keeps a Buy rating on the shares. The company’s EZPLAZ Freeze Dried Plasma,…
Teleflex announces FDA BLA approval of Ezplaz freeze dried plasma
Teleflex (TFX) announced it has received Biologics License Application (BLA) approval for EZPLAZ Freeze Dried Plasma (FDP) from the U.S. Food and Drug Administration (FDA). EZPLAZ FDP is approved for…
Teleflex Announces FDA BLA Approval of EZPLAZ™ Freeze Dried Plasma
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has received Biologics License Application (BLA) approval for EZPL...
FDA grants Teleflex unit license for Ezplaz Freeze Dried Plasma
The Food and Drug Administration said it licensed Ezplaz Freeze Dried Plasma, making it the first freeze-dried plasma product licensed for use in the United States. Ezplaz is intended for…
Teleflex initiated with a Neutral at UBS
UBS analyst Patrick Wood initiated coverage of Teleflex (TFX) with a Neutral rating and $145 price target
Teleflex Announces Second Quarter 2026 Earnings Conference Call Information
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on...
Teleflex awarded national central venous access agreement with Premier
Teleflex Incorporated (TFX) has been awarded a national group purchasing agreement for central venous access products with Premier, Inc (PINC). Effective July 1, 2026, the new agreement allows Premier...
Teleflex Awarded National Central Venous Access Agreement with Premier, Inc.
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) has been awarded a national group purchasing agreement for central venous access products with Premier, Inc. Effective July 1, 2026, the ...
Teleflex price target raised to $145 from $140 at Mizuho
Mizuho raised the firm’s price target on Teleflex (TFX) to $145 from $140 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical device and…
Teleflex initiated with an Outperform at BMO Capital
As previously reported, BMO Capital analyst Vik Chopra initiated coverage of Teleflex (TFX) with an Outperform rating and $159 price target Consensus “hasn’t fully captured” the 2027 EPS bridge and…
Teleflex initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Teleflex (TFX) with an Outperform rating and $159 price target
Teleflex Publishes 2025 Global Impact Report
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it has published its 2025 Global Impact Report. The report outlines r...